Mylan N.V. (MYL) : On Tuesday, The money flowed into the Mylan N.V. (MYL) stock with an uptick to downtick ratio was recorded at 1.17. Transactions worth $43.54 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $37.34 million. The total money flow into the stock was $6.2 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $6.68 million of block transactions on upticks. The total money flow in block trades was $6.68 million. In terms of price action, Mylan N.V. (MYL) traded down $0.47 during the session at $42.75. Compared to the previous days closing, the stock was down only by -1.09%. For the week, the stock is -0.65%, over previous weeks closing.
Also, Major Brokerage house, Leerink Swann maintains its ratings on Mylan N.V. (NASDAQ:MYL). In the latest research report, Leerink Swann raises the target price from $51 per share to $55 per share. According to the latest information available, the shares are now rated Outperform by the analysts at the agency. The rating by the firm was issued on August 15, 2016.
Mylan N.V. has lost 6.29% in the last five trading days and dropped 8.54% in the last 4 weeks. Mylan N.V. has dropped 3.85% during the last 3-month period . Year-to-Date the stock performance stands at -20.94%.
Mylan N.V. (NASDAQ:MYL): The stock opened at $43.25 on Tuesday but the bulls could not build on the opening and the stock topped out at $44.10 for the day. The stock traded down to $42.59 during the day, due to lack of any buying support eventually closed down at $42.75 with a loss of -1.09% for the day. The stock had closed at $43.22 on the previous day. The total traded volume was 4,960,783 shares.
In a related news,The director officer (Chief Executive Officer) of Mylan N.V., Bresch Heather M sold 100,200 shares at $50 on August 9, 2016. The Insider selling transaction had a total value worth of $5,010,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.